NASDAQ:SVRA

Savara (SVRA) Stock Forecast, Price & News

$3.70

-0.04 (-1.07%)

(As of 09/26/2023 ET)

Compare

Today's Range: $3.65
▼
$3.77
50-Day Range: $3.24
▼
$3.88
52-Week Range: $1.08
▼
$4.21

Volume: 494,655 shs
Average Volume: 425,024 shs
Market Capitalization: $500.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Savara MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 35.1% Upside
$5.00 Price Target
Short Interest: Healthy
2.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1.02 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

648th out of 964 stocks

Pharmaceutical Preparations Industry

288th out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Savara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Savara has a forecasted upside of 35.1% from its current price of $3.70.
Amount of Analyst Coverage
Savara has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.68% of the float of Savara has been sold short.
Short Interest Ratio / Days to Cover
Savara has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Savara has recently increased by 1.35%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Savara does not currently pay a dividend.
Dividend Growth
Savara does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SVRA.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Savara this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
4 people have added Savara to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,019,044.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.58% of the stock of Savara is held by insiders.
Percentage Held by Institutions
97.28% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Savara are expected to remain at ($0.29) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Savara is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Savara is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Savara has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

SVRA Price History

30 days | 90 days | 365 days | Advanced Chart

SVRA Stock News Headlines

September 13, 2023 | seekingalpha.com

Molgramostim: Savara's Single Shot At Success

September 11, 2023 | finance.yahoo.com

Savara Inc.'s (NASDAQ:SVRA) Path To Profitability

September 26, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 5, 2023 | finance.yahoo.com

Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023 | msn.com

Savara (SVRA) Price Target Increased by 17.02% to 5.61

August 14, 2023 | msn.com

HC Wainwright & Co. Maintains Savara (SVRA) Buy Recommendation

August 11, 2023 | finance.yahoo.com

Savara Reports Second Quarter Financial Results and Provides Business Update

July 21, 2023 | benzinga.com

10% Owner of Savara Makes $999K Buy

September 26, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

July 20, 2023 | benzinga.com

Savara Recent Insider Activity

July 20, 2023 | benzinga.com

999K Reasons To Be Bullish On Savara Stock

July 16, 2023 | seekingalpha.com

Savara: A Speculative Play

July 13, 2023 | seekingalpha.com

Savara prices $80M common stock and pre-funded warrants offering

July 13, 2023 | marketwatch.com

Savara Shares Near 52-Week High After $80M Offering Prices

July 13, 2023 | marketwatch.com

Savara Prices Share Offering at $3 a Share

July 13, 2023 | finance.yahoo.com

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

June 26, 2023 | msn.com

Savara joins Russell 3000

June 26, 2023 | finance.yahoo.com

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 13, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Evolent Health (EVH), Savara (SVRA)

June 2, 2023 | finance.yahoo.com

Savara to Present at the Jefferies Healthcare Conference

May 28, 2023 | finance.yahoo.com

Independent Director of Savara David Ramsay Buys 4.8% More Shares

May 28, 2023 | finance.yahoo.com

Independent Director of Savara David Ramsay Buys 4.8% More Shares \

May 17, 2023 | msn.com

HC Wainwright & Co. Reiterates Savara (SVRA) Buy Recommendation

May 17, 2023 | markets.businessinsider.com

Savara (SVRA) Gets a Buy from H.C. Wainwright

May 16, 2023 | msn.com

Why Shares of Savara Jumped on Tuesday

May 16, 2023 | msn.com

Savara rises as Jefferies upgrades citing 100% upside

May 15, 2023 | finance.yahoo.com

Savara Reports First Quarter Financial Results and Provides Business Update

See More Headlines

Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Company Calendar

Last Earnings: 8/10/2023
Today: 9/26/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SVRA
Previous Symbol: AMEX:ANX
CUSIP: N/A
CIK: 1160308
Web: www.savarapharma.com
Phone: 512-614-1848
Fax: 858-552-0876
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +33.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,150,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -41.62%
Return on Assets: -31.81%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 18.33
Quick Ratio: 18.33

Sales & Book Value

Annual Sales: $260,000.00
Price / Sales: 1,944.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.95 per share
Price / Book: 3.94

Miscellaneous

Outstanding Shares: 135,170,000
Free Float: 128,982,000
Market Cap: $505.54 million
Optionable: Optionable
Beta: 0.89

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Robert N. Neville (Age 51)
Chairman of the Board, Chief Executive Officer

Taneli Jouhikainen (Age 51)
President, Chief Operating Officer

David L. Lowrance (Age 50)
Chief Financial Officer

Nevan C. Elam (Age 49)
Independent Director

Richard J. Hawkins (Age 68)
Independent Director

Joseph S. McCracken Ph.D. (Age 64)
Independent Director

Matthew Pauls J.D. (Age 46)
Independent Director

Yuri Pikover (Age 56)
Independent Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SVRA Stock - Frequently Asked Questions

Should I buy or sell Savara stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings or view top-rated stocks.
What is Savara's stock price forecast for 2023?: 2 analysts have issued 1 year target prices for Savara's stock. Their SVRA share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts.
How have SVRA shares performed in 2023?: Savara's stock was trading at $1.55 on January 1st, 2023. Since then, SVRA stock has increased by 141.3% and is now trading at $3.74.
View the best growth stocks for 2023 here.
When is Savara's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SVRA earnings forecast.
How were Savara's earnings last quarter?: Savara Inc (NASDAQ:SVRA) issued its earnings results on Thursday, August, 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01.
What other stocks do shareholders of Savara own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?: Savara trades on the NASDAQ under the ticker symbol "SVRA."
Who are Savara's major shareholders?: Savara's stock is owned by a variety of institutional and retail investors. Top institutional investors include Caxton Corp (3.68%), BlackRock Inc. (4.29%), Jennison Associates LLC (2.34%), Geode Capital Management LLC (1.61%), State Street Corp (0.99%) and Northern Trust Corp (0.55%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken, Matthew Pauls, Raymond Dennis Pratt and Rick Yang.
View institutional ownership trends.
How do I buy shares of Savara?: Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Savara's stock price today?: One share of SVRA stock can currently be purchased for approximately $3.74.
How much money does Savara make?: Savara (NASDAQ:SVRA) has a market capitalization of $505.54 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.
How can I contact Savara?: Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial